Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus (Q37841554)

24 August 2017

1 reference

title

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus (English)

1 reference

24 August 2017

0 references

1 reference

Claudine M Chwieduk

1

1 reference

24 August 2017

publication date

1 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

349-361

1 reference

https://scigraph.springernature.com/pub.10.2165/11206060-000000000-00000

24 August 2017

exact match

0 references

cites work

New drugs for type 2 diabetes mellitus: what is their place in therapy?

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Metformin: new understandings, new uses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Clinical pharmacokinetics of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206060-000000000-00000

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

21 January 2018

1 reference

12 December 2020

Metformin hydrochloride: an antihyperglycemic agent.

1 reference

12 December 2020

Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects

1 reference

12 December 2020

Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs

1 reference

12 December 2020

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin

1 reference

12 December 2020

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

1 reference

12 December 2020

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

12 December 2020

10.2165/11206060-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1015727212

0 references

Fatcat ID

release_ev5g6rqtabcmvb5tsjietgysri

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ev5g6rqtabcmvb5tsjietgysri

24 November 2022

mapped directly with Wikidata item

1 reference